Viatris (VTRS) Cash from Operations Growth (1y) (2020 - 2026)
Powered by 
Analysis
Viatris (VTRS) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | 73.78% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.73 Bn | 396.53 Mn | -105.73% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | -125.35% |
| 5 | Bausch Health Companies | 2.31 Bn | 475.75 Mn | 2.10 Bn | 131.83% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | -25.25% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 711.29 Mn | 93.47 Mn | 44.20% |
| 9 | Fennec Pharmaceuticals | 396.40 Mn | 355.15 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.78% |
| Mar 31, 2026 | -27.49% |
| Dec 31, 2025 | 69.01% |
| Sep 30, 2025 | -9.87% |
| Jun 30, 2025 | -42.05% |
| Mar 31, 2025 | -12.87% |
| Dec 31, 2024 | -15.09% |
| Sep 30, 2024 | -1.04% |
| Jun 30, 2024 | -27.80% |
| Mar 31, 2024 | -36.72% |
| Dec 31, 2023 | 200.79% |
| Sep 30, 2023 | -3.89% |
| Jun 30, 2023 | -34.57% |
| Mar 31, 2023 | -14.69% |
| Dec 31, 2022 | -63.87% |
| Sep 30, 2022 | -19.95% |
| Jun 30, 2022 | 43.46% |
| Mar 31, 2022 | 34.13% |
| Dec 31, 2021 | 1,345.03% |
| Mar 31, 2021 | 191.58% |